Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer

Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

Source: In Vivo - November 3, 2020 Category: Research Authors: KOLAROVA, I., DUSEK, L., RYSKA, A., ODRAZKA, K., DOLEZEL, M., VANASEK, J., MELICHAR, B., PETERA, J., BUCHLER, T., VOSMIK, M., PETRAKOVA, K., TERAROVA, P., VILASOVA, Z., JARKOVSKY, J. Tags: Clinical Studies Source Type: research